LANDINE MICHAEL J 4

Accession 0001127602-24-006173

CIK 0001520262other

View on SEC.gov Company Profile

Filed

Feb 20, 7:00 PM ET

Accepted

Feb 21, 5:37 PM ET

Size

51.1 KB

Accession

0001127602-24-006173

Insider Transaction Report

Form 4

Period: 2024-02-18

Alkermes plc.ALKS

LANDINE MICHAEL J

SVP, Corp Dev., Alkermes, Inc.

Transactions

Tax Payment
Ordinary Shares
2024-02-18$32.18/sh−1,308$42,091→ 271,884 total
Other
Employee Stock Option (Right to Buy)
2023-11-17$20.03/sh+1,790$35,854→ 91,335 total
Exercise: $20.03Exp: 2030-02-20→ Ordinary Shares (1,790 underlying)
Exercise/Conversion
Restricted Stock Unit Award
2024-02-20−5,461→ 0 total
→ Ordinary Shares (5,461 underlying)
Exercise/Conversion
Ordinary Shares
2024-02-18+4,448→ 273,192 total
Other
Employee Stock Option (Right to Buy)
2023-11-17$65.94/sh+1,089$71,809→ 55,589 total
Exercise: $65.94Exp: 2028-02-16→ Ordinary Shares (1,089 underlying)
Exercise/Conversion
Ordinary Shares
2024-02-20+5,461→ 277,345 total
Other
Restricted Stock Unit Award
2023-11-17+319→ 16,310 total
→ Ordinary Shares (319 underlying)
Other
Employee Stock Option (Right to Buy)
2023-11-17$31.64/sh+1,519$48,061→ 77,519 total
Exercise: $31.64Exp: 2026-02-28→ Ordinary Shares (1,519 underlying)
Other
Restricted Stock Unit Award
2023-11-17+221→ 11,309 total
→ Ordinary Shares (221 underlying)
Tax Payment
Ordinary Shares
2024-02-20$30.39/sh−1,606$48,806→ 275,739 total
Other
Employee Stock Option (Right to Buy)
2023-11-17$46.24/sh+999$46,194→ 50,999 total
Exercise: $46.24Exp: 2024-03-03→ Ordinary Shares (999 underlying)
Other
Employee Stock Option (Right to Buy)
2023-11-17$31.93/sh+1,811$57,825→ 92,411 total
Exercise: $31.93Exp: 2029-02-21→ Ordinary Shares (1,811 underlying)
Other
Restricted Stock Unit Award
2023-11-17+107→ 5,461 total
→ Ordinary Shares (107 underlying)
Other
Restricted Stock Unit Award
2023-11-17+261→ 13,345 total
→ Ordinary Shares (261 underlying)
Other
Employee Stock Option (Right to Buy)
2023-11-17$69.83/sh+879$61,381→ 44,879 total
Exercise: $69.83Exp: 2025-02-26→ Ordinary Shares (879 underlying)
Other
Employee Stock Option (Right to Buy)
2023-11-17$26.82/sh+1,279$34,303→ 65,241 total
Exercise: $26.82Exp: 2033-02-23→ Ordinary Shares (1,279 underlying)
Exercise/Conversion
Restricted Stock Unit Award
2024-02-18−4,448→ 8,897 total
→ Ordinary Shares (4,448 underlying)
Other
Employee Stock Option (Right to Buy)
2023-11-17$19.34/sh+1,809$34,986→ 92,296 total
Exercise: $19.34Exp: 2031-02-22→ Ordinary Shares (1,809 underlying)
Other
Employee Stock Option (Right to Buy)
2023-11-17$24.59/sh+1,394$34,278→ 71,171 total
Exercise: $24.59Exp: 2032-02-18→ Ordinary Shares (1,394 underlying)
Other
Employee Stock Option (Right to Buy)
2023-11-17$53.50/sh+999$53,447→ 50,999 total
Exercise: $53.50Exp: 2027-02-17→ Ordinary Shares (999 underlying)

Footnotes (11)

[F1]Each restricted stock unit represents a contingent right to receive one ordinary share.
[F10]Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.
[F11]Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.
[F2]Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
[F3]These options are fully vested in accordance with their terms.
[F4]Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.
[F5]Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.
[F6]Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.
[F7]Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.
[F8]Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.
[F9]Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

Documents

2 files

Issuer

Alkermes plc.

CIK 0001520262

→

Entity typeother

Related Parties

filerCIK 0001235600

Filing Metadata

Form type: 4
Filed: Feb 20, 7:00 PM ET
Accepted: Feb 21, 5:37 PM ET
Size: 51.1 KB

View on SEC.gov